Huiyu Pharmaceutical (688553.SH) has two subsidiaries that received multiple overseas listing permits for pharmaceuticals.

Huiyu Pharmaceutical (688553.SH) announced that its subsidiary Seacross Pharma (E...

Zhitong FinanceFeb 24 04:36 ET

Sichuan Huiyu Pharmaceutical Secures Overseas Market Approvals for Key Products

MT NewswiresFeb 11 02:13 ET

Huiyu Pharma's Calcium Folinate Injection Gets Registration Certificate

MT NewswiresJan 29 00:08 ET

2024 Annual Results Forecast

SZSIJan 24 11:00 ET · Announcements

Huiyu Pharmaceutical (688553.SH): The net profit for 2024 is expected to increase by 114.61% to 157.54%.

Gelonghui January 24丨Huiyu Pharmaceutical (688553.SH) announced the annual performance forecast for 2024, expecting the net income attributable to owners of the parent company to be between 300 million yuan and 360 million yuan, an increase of 114.61% to 157.54% compared to the same period last year (statutory disclosure data). It is expected that the net income attributable to owners of the parent company, after deducting non-recurring gains and losses, will be between 95 million yuan and 110 million yuan, an increase of 43% compared to the same period last year (statutory disclosure data).

Gelonghui FinanceJan 24 07:26 ET

Sichuan Huiyu Pharmaceutical Obtains Ireland's Marketing Authorization for Anti-Infection Drug

MT NewswiresJan 17 02:56 ET